全数字化乳腺X线立体定位及活检技术对早期乳腺癌诊断及治疗的价值

目的探讨全数字化乳腺X线立体定位及活检技术对早期乳腺癌的诊断及治疗价值。资料与方法回顾性总结36例临床未触及病变,仅X线摄影发现乳腺微小病变患者的临床及影像资料,用全数字化X线立体定位导丝导向切除活检(stereotactic needle localized biopsy,SNLB)或核芯针穿刺活检(stereotactic core needle biopsy,SCNB)。结果 30例行SNLB患者中,29例一次性成功,成功率达96.7%;6例行SCNB者中,1例乳腺癌漏诊。结论应用全数字化乳腺X线立体定位及活检技术,可有效提高早期乳腺癌的诊断率,可对微创手术治疗提供精确的导向作用。     

立体定位穿刺留置导丝引导手术活检隐匿性乳腺病灶

目的　评价立体定位穿刺留置导丝引导手术活检术对临床触诊阴性而乳腺X线摄影发现的隐匿性乳腺病变定位活检的价值。材料与方法　临床扪诊阴性 ,而乳腺X线片显示成簇的细小钙化、模糊小结节及局部结构紊乱等可疑的恶性病灶 ,通过计算机立体定位下穿刺 ,留置导丝于可疑的病灶区 ,然后手术取活体组织行病理学检查。结果　 31例患者 ,乳腺X线检查发现病灶34个 ,定位穿刺留置导丝 32根 ,导丝引导下手术活检 32例次均一次性成功定位与切除 ,定性诊断正确率为 10 0 %。病理检查结果 :恶性病变 9例次 11个病灶 ,良性病变 2 3例次。恶性病变中浸润性导管癌 4例次 5个病灶 ,导管内癌 3例次 ,乳腺单纯癌 2例次 3个病灶。结论　立体定位穿刺留置导丝引导手术活检术对乳腺隐匿性病变定位活检准确 ,既解决了外科医生术中对乳腺微小的病变定位的困难 ,又解决了盲目手术切除或针穿活检假阴性的问题。此技术创伤小 ,简单易行 ,是目前诊断早期乳腺癌的有效方法和技术保证     

X线立体穿刺钩针定位在乳腺微小病变中的应用

目的:探讨X线立体穿刺钩针定位对不可触及乳腺微小病变的诊断价值.方法:回顾分析87例乳腺钼靶X线立体穿刺钩针定位病例,均为临床触诊阴性而乳腺钼靶X线片显示有微小病变,采用钩针定位后,留置导丝于定位区,引导手术将病灶切除活检.结果:83位患者,乳腺X线检查发现病灶87例,导丝引导下手术活检均一次性成功定位与切除,定性诊断正确率为100%.病理检查结果:恶性病变8例,良性病变79例.结论:X线立体穿刺钩针定位简单易行,在乳腺微小病变的诊断中起着重要的作用.     

X线钼靶及立体定位活检在诊断乳腺腺病中的应用

目的探讨乳腺腺病的X线表现及在立体定位活检中的应用。方法分析2011年1月至2012年10月在我院就诊的60例乳腺腺病患者的临床资料及影像学表现。所有患者均经X线钼靶及立体定位活检手术病理证实。结果患者年龄29～84岁,平均45.2岁。14例患者可触及乳腺结节,7例患者有乳腺癌家族史。X线表现:38例(63%)X线表现为单纯钙化,其中簇状钙化24例,13例(22%)表现为单纯结节,6例(10%)结节内部或边缘伴钙化,3例(5%)表现为局部腺体密度增高或结构紊乱,其中1例伴钙化。结论钙化是乳腺腺病最常见的X线征象。乳腺腺病缺乏特异性影像学特征,全数字化乳腺X线立体定位核芯针穿刺活检或立体定位导丝导向切除活检可对病变的良、恶性作出鉴别。     

钼靶X线定位穿刺留置导丝活检对乳腺微小病灶的诊断价值

目的探讨乳腺X线定位穿刺留置导丝活检术对乳腺微小病灶的诊断价值。方法回顾分析临床触诊阴性而乳腺钼靶X线片显示的微小病灶28例,采用乳腺钼靶X线定位下穿刺,留置导丝于微小病灶区,引导手术将病灶切除活检。结果28例微小病灶均一次性定位成功,定位满意率93%,手术切除完整。病理检查:恶性病变9例,其中浸润性导管癌5例,导管内癌伴早期浸润1例,导管内癌2例,髓样癌1例;良性病变19例。结论乳腺钼靶X线定位穿刺留置导丝活检术,定位准确,诊断明确,能确定乳腺微小病灶的性质,是目前诊断早期乳腺癌的有效方法。     

钨铑靶立体定位在乳腺病变穿刺中的应用价值

目的 探讨全数字化钨铑靶乳腺机三维立体定位系统在乳腺病变穿刺活检术中的应用价值.方法 对102例乳腺摄影发现病变的患者均行乳腺X线下三维立体定位穿刺,抽取部分组织进行活检,结合病理结果进行分析.结果 102例三维立体定位穿刺中,一次性准确定位穿刺97例,成功率为95％,3例定位穿刺多次,另有1例因乳房厚度小于射程,穿刺点无法准确选取.病理结果乳腺癌63例,占61.8％,乳腺良性病变39例,占38.2％.结论 全数字化钨铑靶乳腺机三维立体定位穿刺术,具有操作简便,安全可靠,定位精确,成功率高等优点,能较早地明确乳腺病变的定性诊断,尤其对临床未触及肿块、超声阴性的早期乳腺癌具有重要的临床价值.     

术前导丝穿刺定位对可疑乳腺癌病灶的诊断价值

目的:探讨术前导丝穿刺定位对可疑乳癌病灶的诊断价值.方法:依据钼靶X线影像资料,搜集可疑乳癌病灶患者42例,采用X线导丝穿刺定位,留置导丝于病灶区,引导手术行病灶切除活检,病例均经组织病理证实.结果:经定位术后病变切除率达100%,其中,乳腺癌15例,乳腺增生症20例,良性乳腺肿瘤4例,炎症病变2例,脂肪坏死1例.结论:乳腺导丝定位术安全可靠,对引导切除可疑乳癌病灶具有很高的应用价值.     

全数字化乳腺X线摄影二维钢丝定位的临床应用分析

目的探讨全数字化乳腺X线摄影立体穿刺定位活检术在隐匿性乳腺疾病临床诊断中的应用价值。方法对54例患者进行全数字化乳腺X线摄影立体穿刺定位活检术,手术病理结果进行对比分析。结果在接受SNLB检查的54例患者中有29例呈现簇状颗粒样、泥沙样、混合性钙化,直径≤10mm;8例结节伴钙化;12例单纯结节;5例局限性结构紊乱,呈现放射状毛刺或"星芒征"。所有患者定位满意,全部定位成功。手术病理结果:其中乳腺导管内原位癌17例、纤维腺瘤11例、腺病9例、导管上皮不典型增生5例、导管上皮增生4例、浸润性导管癌3例、导管内乳头状瘤2例、囊性增生病2例、粘液癌1例。结论全数字化乳腺X线摄影立体穿刺定位活检术可以有效应用全数字化乳腺X光机及配套进行立体定位活检系统,获得的病理诊断准确、可靠,可有效提高对早期乳腺癌的诊断能力,能够获得可靠的病理结果,并可对微创手术治疗提供精确的导向作用,同时完成诊断和治疗。     

钨铑靶立体定位在乳腺病变穿刺中的应用价值北大核心CSCD

目的探讨全数字化钨铑靶乳腺机三维立体定位系统在乳腺病变穿刺活检术中的应用价值。方法对102例乳腺摄影发现病变的患者均行乳腺X线下三维立体定位穿刺,抽取部分组织进行活检,结合病理结果进行分析。结果 102例三维立体定位穿刺中,一次性准确定位穿刺97例,成功率为95%,3例定位穿刺多次,另有1例因乳房厚度小于射程,穿刺点无法准确选取。病理结果乳腺癌63例,占61.8%,乳腺良性病变39例,占38.2%。结论全数字化钨铑靶乳腺机三维立体定位穿刺术,具有操作简便,安全可靠,定位精确,成功率高等优点,能较早地明确乳腺病变的定性诊断,尤其对临床未触及肿块、超声阴性的早期乳腺癌具有重要的临床价值。     

立体定位穿刺活检术对乳腺微小病变定性诊断的探讨

目的提高乳腺X线立体定位核芯针活检(SCNB)、立体定位穿刺导丝定位活检(SNLB)对乳腺微小病变的定性诊断准确性及成功率。方法回顾性分析了118例乳腺微小病变立体定位穿刺导丝定位活检及核芯针活检的病理资料,并与手术病理结果进行对照。结果SCNB 33例中31例活检成功,24例行外科手术,恶性病变8例,良性病变16例,诊断符合率为87.5%,误诊3例(12.5%),7例随访。2例出现迷走神经反应,未完成检查。拟行SNLB 85例,83例定位成功,其中80例定位满意,满意率94%,3例定位偏离,2例定位失败,恶性病变30例,良性病变53例。结论SCNB及SNLB是目前对乳腺微小病灶定性诊断的主要方法,通过合理选择应用可提高诊断准确性及成功率。     

乳腺X线立体定位穿刺活检技术的应用

目的　探究乳腺X线立体定位穿刺活检技术 (SCNB)及其在乳腺疾病诊断上的应用。方法　对 38个乳腺病变区进行SC NB检查 ,并与手术病理对照 ,分析SCNB技术的操作方法与技巧。结果　对 38个乳腺病变的检查 ,诊断符合率为 84.2 %,无假阳性 ;穿刺失误及假阴性各占 7.89%。结论　本技术对应用取材部位的深度由电子计算机指导完成 ,定位准确 ,操作简单 ,安全可靠。熟练掌握SCNB技术 ,可望提高早期癌的诊断水平。     

X线立体定位细针活检诊断不可触及的乳腺病变

目的 :探讨乳腺X线立体定位细针活检技术诊断不可触及的乳腺病灶的价值。材料和方法 :对 2 7例临床不能触及 ,而X线片上显示的乳腺微小病变 ,通过X线立体定位穿刺 ,放入钢丝定位后指导外科切检 ,进行组织病理学检查。结果 :2 7个乳腺病变 ,恶性病变 7例 ,其中T0 期 3例 ,T1期 4例 ;良性病变 2 0例 ,含慢性囊性乳腺病 10例 (其中合并导管上皮异型增生及上皮增生活跃各 3例 ) ,小叶增生 3例 ,慢性炎症 3例 ,腺纤维瘤 2例 ,导管内乳头状瘤 1例 ,错钩瘤 1例。结论 :立体定位细针活检对不可触及的乳腺病变的定位定性诊断以及对早期乳腺癌的诊断有重要价值。     

Stereotactic breast biopsy with a biopsy gun

One hundred three patients underwent stereotactic breast biopsy with an 18-, 16-, or 14-gauge cutting needle and a biopsy gun. After biopsy, a localization wire was placed and surgical biopsy performed. There was agreement of the histologic results in 89 cases (87%) including 14 of 16 cancers (87%) (kappa = 0.806). The gun biopsy yielded the correct diagnosis in four cases involving a lesion (including one cancer) that was missed at the surgical biopsy. Nine cases in which the lesion was missed at gun biopsy can be related to insufficient needle size, the greater difficulty in using one of the two stereotactic devices, and early inexperience with the technique. A 14-gauge needle was used in the last 29 biopsies, the results of which agreed with the surgical pathologic findings in 28 cases (97%). With greater experience, stereotactic-guided large-gauge automated percutaneous biopsy may prove to be an acceptable alternative to surgical biopsy in women with breast masses suspected at mammography.     

钼靶X线引导下定位FNAC或CNB及其对乳腺微小病变的诊断价值

目的探讨钼靶X线引导下定位细针穿刺抽吸细胞学检查(fineneedleaspirationcytology,FNAC)或针芯组织学活检术(coreneedlebiopsy,CNB)及其对乳腺微小病变的诊断价值。方法经病理证实的34例35个乳腺微小病变均先行常规钼靶X线摄片,再在钼靶X线引导下定位FNAC或CNB。以手术病理为金标准回顾性分析35个乳腺微小病变的初期钼靶X线诊断率和中期钼靶X线诊断率。随机抽取经手术病理证实的30例30个未行钼靶X线引导下定位FNAC或CNB的乳腺微小病变作为对照。结果钼靶X线引导下35个病变FNAC或CNB均定位成功。2组初步钼靶X线的正确诊断率分别为60%和53.3%(P>0.5),无明显差异。研究组中期钼靶X线的正确诊断率与对照组初步钼靶X线的正确诊断率分别为82.9%和53.3%(P<0.05),有明显差异。结论钼靶X线引导下定位FNAC或CNB操作过程简便、经济、安全,定位准确率高。中期钼靶X线正确诊断率明显提高。     

Stereotactic and sonographic large-core biopsy of nonpalpable breast lesions: results of the Radiologic Diagnostic Oncology Group V study

RATIONALE AND OBJECTIVES: To determine the diagnostic accuracy of stereotactically and sonographically guided core biopsy (CB) for the diagnosis of nonpalpable breast lesions. MATERIALS AND METHODS: Twenty-two institutions enrolled 2,403 women who underwent imaging-guided fine needle aspiration followed by imaging-guided large-CB of nonpalpable breast abnormalities. All mammograms were reviewed for study eligibility by one of two breast imaging radiologists. The protocol for image-guided biopsy, using either ultrasound (USCB) or stereotactic (SCB) guidance, was standardized at all institutions and all biopsy specimens were over-read by one of three expert pathologists. Patients with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia, or lobular neoplasia on CB underwent surgical excision. Those with negative CB but suspicious ("discordant") pre-biopsy mammography also underwent surgical excision. Patients having a negative CB that was concordant with the pre-biopsy mammography suspicion were assigned to follow-up mammography at 6, 12, and 24 months following CB. RESULTS: A gold standard diagnosis based on definitive histopathologic diagnosis, mammography follow-up, or an imputed gold standard diagnosis was established for 1,681 patients. Of 310 cases with a gold standard diagnosis of invasive breast carcinoma, 261 (84.2%) were invasive carcinoma, 31 (10%) were ductal carcinoma in situ (DCIS), four (1.3%) were ADH, one (0.3%) was a non-breast cancer, and 13 (4.2%) were benign on CB. For 138 cases with a gold standard diagnosis of DCIS, 113 (81.9%) were DCIS, 20 (14.5%) were ADH, and five (3.6%) were benign on CB. For 57 cases (13 masses, 44 calcifications) with an initial CB diagnosis of ADH, atypical lobular hyperplasia or lobular neoplasia, 20 (35.1%) had a gold standard diagnosis of DCIS (4 masses, 16 calcifications) and four (7.0%) had a gold standard diagnosis of invasive cancer (4 calcifications). Of 144 cases (22 masses, 122 calcifications) with an initial CB diagnosis of DCIS, 31 (21.5%) had a gold standard diagnosis of invasive cancer (10 masses, 21 calcifications). The sensitivity, specificity and accuracy for CB by either imaging guidance method in this trial were .91, 1.00, and .98, respectively. The sensitivity, predictive value negative, and accuracy of CB for diagnosing masses (.96, .99, and .99, respectively) were significantly greater (P < .001) than for calcifications (.84, .94, and .96, respectively). The sensitivity (.89) of SCB for diagnosing all lesions was significantly lower (P = 0.029) than that of USCB (.97) because of the preponderance of calcifications biopsied by SCB versus USCB. There was no difference between USCB and SCB in sensitivity, predictive value negative, or accuracy for the diagnosis of masses (97.3, 98.9, and 99.2, respectively for USCB; 95.6, 98.5, and 98.9 respectively for SCB). CONCLUSION: Percutaneous, imaged-guided core breast biopsy is an accurate diagnostic alternative to surgical biopsy in women with mammographically detected suspicious breast lesions.     

早期乳腺癌临床诊断分析

 目的 探讨早期乳腺癌临床特点,寻找提高早期乳腺癌诊断率的方法.方法 回顾性分析69例早期乳腺癌的临床资料.结果 乳腺局限性增厚42例(61%),可触及结节者仅24例(34.8%);有乳腺增生病史伴增生症状加重者50例(72.5%).钼靶X线单纯钙化27例(39.1%),肿块结节影11例(15.9%).56例(81.2%)超声检出边界不规则低回声结节,78.6%的结节内或周围可测到血流信号.25例通过空芯针穿刺获得诊断,44例由超声或钼靶定位后手术活检确诊.结论 高危因素妇女乳腺增生症状加重、乳腺局限性增厚是早期乳腺癌的重要表现;彩色多普勒超声对早期乳腺癌的诊断价值可能优于钼靶X线检查;及时对乳腺结节、局限性增厚等可疑病灶行组织学穿刺活检或在超声、钼靶定位后手术活检,可提高早期乳腺癌的诊断率.     

X线定位对乳腺隐匿性病灶活检术的临床应用

目的 探讨应用乳腺常规和立体定位方法对临床隐匿性乳腺病变进行细针穿刺导丝定位活检术的应用价值。材料与方法 回顾1997年10月－2000年10月间对39例临床未触及乳腺病变的患者采用细针定位活检术,其中常规定位法27例,立体定位法12例。结果 （1）病理结果：39例中,发现早期民腺癌7例（导管原位癌2例）,乳腺小叶增生9例（2例伴有非典型性增生）,硬化性腺病6例（5例伴有上皮增生活跃）,纤维腺瘤12例,乳头状瘤3例,浆细胞性乳腺炎2例。（2）两种定位方法满意率比较：立体定位12例,全部一次定位成功,满意率为100％;常规定位25例一次定位成功,满意率为93％。两组数据经χ^2检验（P＞0．05）。（3）两种定位方法所用时间：立体定位平均每人次为41．6分钟。常规比立体定位节省时间平均每人次15．4分钟。结论 对临床不可触及、X线检查确有明显异常的乳腺病变,应积极采用细针定位后外科活检。常规定位法是一种简便、快捷和较准确的定位方法,可作为乳腺细针穿刺导丝定位的首选方法。     

Stereotactic vacuum-assisted breast biopsy (Mammotome biopsy) for non-palpable microcalcification on mammography

PURPOSE: The purpose of this study was to assess the benefits of stereotactic vacuum-assisted breast biopsy in patients with non-palpable microcalcification detected on mammography. METHODS: Between October 2001 and November 2003, stereotactic Mammotome biopsies were performed for 150 microcalcified lesions on mammography using the prone-type stereotactic vacuum-assisted breast biopsy system (Mammotest and Mammovision, Fischer, Denver, USA) . The mammography findings were classified according to the guidelines of The Japan Radiological Society/The Japan Association of Radiological Technologists. Ninety-eight cases were category 3, 38 were category 4, and 14 were category 5. RESULTS: All cases were determined to be cases of microcalcification by specimen radiography or histology. Complications were negligible. One hundred twenty of the cases were mastopathy, and 30 of them were breast cancer (14 were ductal carcinoma in situ, 7 were ductal carcinoma in situ with microinvasion, and 9 were invasive ductal carcinoma). Twenty-seven breast cancers were diagnosed as category 4 or 5 (51.9%) on mammography. The operative stages of 27 cases were as follows: 7 were stage 0, 17 were stage 1, and 3 were stage 2A. Twenty-four of 27 (88.9%) were early breast cancers. CONCLUSION: Mammotome biopsy is a safe and useful modality for the histological diagnosis of non-palpable microcalcifications.